Dentons (Paris and London) has assisted Théa Open Innovation with the signature of a partnership agreement with Link Biologics, including an equity investment from Théa Open Innovation, to develop Link_TSG6, a biologic drug for Dry Eye Disease (DED) worldwide (excluding Asia). Link_TSG6 is a biological drug based on human TSG-6, a protein that plays an […]
The post Dentons advises Théa Open Innovation on a partnership with Link Biologics to co-develop a biologic drug for Dry Eye Disease appeared first on Legal Desire Media and Insights.